trial

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia

NCTId NCT01829048
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 37 (actual)
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary completion 2013-10-17
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
37 (actual)
Study type
Interventional
Allocation
Randomized
Model
—
Masking
Double
Start
2013-03-06
Primary completion
2013-10-17
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
PF-02545920

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor

Sites

1 total
Glendale, United States

Facts & assertions

4 sourced
Enrollment
37
Phase
PHASE1
Primary Completion Date
2013-10-17
Status
COMPLETED
relationships
The graph out of here
drug
PF-02545920
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication